Check out the VA for long term outcomes of EMPA Kidney by Oscar Duron
Estudio post EMPA-KIDNEY_El Resumen Visual
El estudio post EMPA-KIDNEY, evaluó los efectos de la empagliflozina en pacientes con enfermedad renal crónica. Los hallazgos mostraron que este tratamiento no solo proporcionó beneficios cardiorrenales significativos durante la fase activa del estudio, sino que también mantuvo estos efectos positivos por hasta 12 meses después de la interrupción del tratamiento.
Revisa el resumen visual realizado por Oscar Durón y únete a la conversación en nuestro próximo #NephJC
FLOZINATing to the Future- Long Term Effects of Empagliflozin in Patients with CKD
🤔 EMPA KIDNEY analysis by CKD diagnosis
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial (The EMPA-KIDNEY Collaborative Group The Lancet 2023)
🤔 EMPA Kidney sub-group analysis by DM and ACR status
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial (The EMPA-KIDNEY Collaborative Group 2023)
Freely Filtered does EMPA-Kidney
Freely Filtered 054: EMPA-Kidney. EMPA-Kidney is the last of the big three to report their Kidney Endpoints SGLT2i trial (CREDENCE for Cana, DAPA-CKD for Dapa, and now EMPA-Kidney for Empa) and it answers some questions that had previously been unanswered. Join the Filtrate as they tear it apart.
Another EMPA-Kidney Tweetorial
Friend of NephJC, Daniel Schwartz does a nice tweetorial on EMPA-Kidney
Flozins strike again!
If you missed the biggest NephJC of the year, at least read the highlights here.
